Principia utilizes its Tailored Covalency® technology to discover and develop safe, effective and convenient oral therapies that have the potential to become standard of care for patients with autoimmune and inflammatory diseases as well as cancer. 

Phase 1
Phase 2
PRN1008: BTK inhibitor / Pemphigus Vulgaris
PRN1008: BTK inhibitor / Second Indication
PRN1371: FGFR inhibitor / Multiple Cancers
PRN2246: BTK inhibitor / CNS, Autoimmune/Inflamm
Immunoproteasome Inhibitor: Autoimmune / Inflamm